End Price Gouging for Medications Act
Sen. Merkley Introduces Bill to Cap U.S. Drug Prices at Lowest Rates Paid by Other Wealthy Nations
This bill is currently in the early stages of the legislative process and is being reviewed by the Senate Committee on Health, Education, Labor, and Pensions. It is considered active, but there are no upcoming votes or hearings scheduled at this time. The bill does not have a companion bill listed.
Legislative Progress
While lowering drug costs is very popular with voters, this specific plan faces intense opposition from the pharmaceutical industry and lacks the Republican support needed to pass the Senate.
Key Points
Impact Analysis
Personal Impact
Life & Work
Small business owners who provide health insurance to their employees could see lower premiums over time as drug prices drop across the board. The bill's requirement that manufacturers offer reference prices to all purchasers, including those with group health plans, means employer-sponsored insurance costs could decrease.
Programs
Disabilities
Milestones
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Source Information
Document Type
Congressional Bill
Official Title
End Price Gouging for Medications Act
Data Sources
Sponsor
Cosponsors
(3)Analysis generated by AI. Always verify with official sources.